TEVA Q1 2024 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B+4.3% YoY

Gross Profit

$1.8B46.4% margin

Operating Income

-$218M-5.7% margin

Net Income

-$139M-3.6% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-14.3%

Cash Flow

Operating Cash Flow

-$124M

Free Cash Flow

-$248M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$42.8B

Total Liabilities

$35.2B

Stockholders' Equity

$7.3B

Cash & Equivalents

$3.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.7B	+4.3%
Gross Profit	$1.8B	$1.6B	+11.9%
Operating Income	-$218M	-$13M	-1576.9%
Net Income	-$139M	-$220M	+36.8%